Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial.

KAN-101 - Anokion

http://www.ncbi.nlm.nih.gov/pubmed/37329900

Dina Wassaf; Helen Stacey; Joseph A Murray; Kaela E Goldstein; Karen Dunn; Kristie M Grebe; Peter Winkle; Rajesh Manchanda; Samir Arora; Simon Cooper; Stephan Kontos

Jun 18, 2023